Previous epitope-based cancer vaccines have focused on analyzing a limited number of
mutated epitopes and clinical variables preliminarily to experimental trials. As a result …

The current epitope selection methods for peptide vaccines often rely on epitope binding
affinity predictions, prompting the need for the development of more sophisticated in silico …

Somatic mutations binding to the patient's MHC and recognized by autologous T cells
(neoepitopes) are ideal cancer vaccine targets. They combine a favorable safety profile due …

Immunotherapy is currently recognized as the fourth modality in cancer therapy. CTL can
detect cancer cells via complexes involving human leukocyte antigen (HLA) class I …

Introduction The field of cancer therapy has undergone a major transformation in less than a
decade due to the introduction of checkpoint inhibitors, the advent of next generation …

Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the
goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still …

Background The integration of genomics with immunotherapy has potential value for cancer
vaccine development. Given the clinical successes of immune checkpoint modulators …

Therapeutic vaccines targeting mutant tumor antigens (“neoantigens”) are an increasingly
popular form of personalized cancer immunotherapy. Vaxrank is a computational tool for …

Cancer (treatment) vaccines that are made of neoantigens, or peptides unique to tumor cells
due to somatic mutations, have emerged as a promising method to reinvigorate the immune …

Somatic mutations in cancers affecting protein coding genes can give rise to potentially
therapeutic neoepitopes. These neoepitopes can guide Adoptive Cell Therapies and …